Type 2 Diabetes and Thiazide Diuretics.

[en] PURPOSE OF REVIEW: In patients with prediabetes or type 2 diabetes, the use of thiazides as antihypertensive agents has been challenged because associated metabolic adverse events, including new-onset diabetes. RECENT FINDINGS: These metabolic disturbances are less marked with low-dose thiazides and, in most but not all studies, with thiazide-like diuretics (chlorthalidone, indapamide) than with thiazide-type diuretics (hydrochlorothiazide). In post hoc analyses of subgroups of patients with hypertension and type 2 diabetes, thiazides resulted in a significant reduction in cardiovascular events, all-cause mortality, and hospitalization for heart failure compared to placebo and generally were shown to be non-inferior to other antihypertensive agents. Benefits attributed to thiazide diuretics in terms of cardiovascular event reduction outweigh the risk of worsening glucose control in type 2 diabetes and of new-onset diabetes in non-diabetic patients. Thiazides still play a key role in the management of patients with type 2 diabetes and hypertension.

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

English

Title :

Type 2 Diabetes and Thiazide Diuretics.

Publication date :

2018

Journal title :

Current Diabetes Reports

ISSN :

1534-4827

eISSN :

1539-0829

Publisher :

Current Science, United States

Volume :

Issue :

Pages :

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 26 March 2018

Statistics

Number of views

87 (2 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther. 2014;19(1):5–13. https://doi.org/10.1177/1074248413497257.
Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380(9841):601–10. https://doi.org/10.1016/S0140-6736(12)60987-8.
McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2(10):843–51. https://doi.org/10.1016/S2213-8587(14)70031-2.
Bahtiyar G, Gutterman D, Lebovitz H. Heart failure: a major cardiovascular complication of diabetes mellitus. Curr Diabetes Rep. 2016;16(11):116. https://doi.org/10.1007/s11892-016-0809-4.
Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991–1006. https://doi.org/10.1161/CIRCRESAHA.116.305697.
Grossman E, Verdecchia P, Shamiss A, Angeli F, Reboldi G. Diuretic treatment of hypertension. Diabetes Care. 2011;34(Suppl 2):S313–9. https://doi.org/10.2337/dc11-s246.
Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich). 2011;13(9):639–43. https://doi.org/10.1111/j.1751-7176.2011.00512.x.
Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother. 2014;15(4):527–47. https://doi.org/10.1517/14656566.2014.879118.
Rosendorff C. Why are we still using hydrochlorothiazide? J Clin Hypertens (Greenwich). 2011;13(12):867–9. https://doi.org/10.1111/j.1751-7176.2011.00566.x.
DiNicolantonio JJ, Bhutani J, Lavie CJ, O’Keefe JH. Evidence-based diuretics: focus on chlorthalidone and indapamide. Futur Cardiol. 2015;11(2):203–17. https://doi.org/10.2217/fca.14.83.
Robinson DM, Wellington K. Indapamide sustained release: a review of its use in the treatment of hypertension. Drugs. 2006;66(2):257–71. https://doi.org/10.2165/00003495-200666020-00011.
Salvetti A, Ghiadoni L. Thiazide diuretics in the treatment of hypertension: an update. J Am Soc Nephrol. 2006;17(4 Suppl 2):S25–9. https://doi.org/10.1681/ASN.2005121329.
Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165(12):1401–9. https://doi.org/10.1001/archinte.165.12.1401.
Sica DA. Diuretic-related side effects: development and treatment. J Clin Hypertens (Greenwich). 2004;6(9):532–40.
Cooper-DeHoff RM. Thiazide-induced dysglycemia: it’s time to take notice. Expert Rev Cardiovasc Ther. 2008;6(10):1291–4. https://doi.org/10.1586/14779072.6.10.1291.
Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-induced hyperglycaemia and diabetes. Drug Saf. 2015;38(12):1153–68. https://doi.org/10.1007/s40264-015-0339-z.
Warram JH, Laffel LM, Valsania P, Christlieb AR, Krolewski AS. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med. 1991;151(7):1350–6. https://doi.org/10.1001/archinte.1991.00400070114014.
• Lin JJ, Chang HC, Ku CT, Chen HY. Hydrochlorothiazide hypertension treatment induced metabolic effects in type 2 diabetes: a meta-analysis of parallel-design RCTs. Eur Rev Med Pharmacol Sci. 2016;20(13):2926–46. This meta-analysis concludes that while thiazide diuretics are still a recommended medication of hypertension therapy for type 2 diabetes, treatment with low-dose HCTZ should be attempted to evaluate the effectiveness and adverse metabolic effects.
•• Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10—should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35(5):922–44. https://doi.org/10.1097/HJH.0000000000001276. This systematic review compares the effects on cardiovascular and renal outcomes of blood pressure lowering by different drug classes in patients with and without diabetes mellitus.
• Liang W, Ma H, Cao L, Yan W, Yang J. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis. J Cell Mol Med. 2017;21(11):2634–42. https://doi.org/10.1111/jcmm.13205. This comparative meta-analysis concludes that using thiazide-like diuretics is superior to thiazide-type diuretics in reducing blood pressure without increasing the incidence of metabolic disturbances.
• Yang Y, Xu H. Comparing six antihypertensive medication classes for preventing new-onset diabetes mellitus among hypertensive patients: a network meta-analysis. J Cell Mol Med. 2017;21(9):1742–50. https://doi.org/10.1111/jcmm.13096. This network meta-analysis concludes that hydrochlorothiazide exhibits a reliable performance in comparison with other antihypertensive agents although RAS blockers appear superior.
• Brunstrom M, Eliasson M, Nilsson PM, Carlberg B. Blood pressure treatment levels and choice of antihypertensive agent in people with diabetes mellitus: an overview of systematic reviews. J Hypertens. 2017;35(3):453–62. https://doi.org/10.1097/HJH.0000000000001183. This paper concludes that the available evidence supports treatment in people with type 2 diabetes and systolic blood pressure more than 140 mmHg, using any of the major antihypertensive drug classes, includinf thiazide diuretics.
• Zhang X, Zhao Q. Association of thiazide-type diuretics with glycemic changes in hypertensive patients: a systematic review and meta-analysis of randomized controlled clinical trials. J Clin Hypertens (Greenwich). 2016;18(4):342–51. https://doi.org/10.1111/jch.12679. This meta-analysis concludes that thiazide-type diuretics are associated with significant but small adverse glycemic effects in hypertensive patients and that a lower dose might reduce or avoid glycemic changes.
•• Remonti LR, Dias S, Leitao CB, Kramer CK, Klassman LP, Welton NJ, et al. Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes—network meta-analysis of randomized trials. J Diabetes Complicat. 2016;30(6):1192–200. https://doi.org/10.1016/j.jdiacomp.2016.04.020. This network meta-analysis concludes that there is no benefit of a single antihypertensive class in reduction of mortality in hypertensive patients with type 2 diabetes.
Mukete BN, Rosendorff C. Effects of low-dose thiazide diuretics on fasting plasma glucose and serum potassium-a meta-analysis. J Am Soc Hypertens. 2013;7(6):454–66. https://doi.org/10.1016/j.jash.2013.05.004.
Helderman JH, Elahi D, Andersen DK, Raizes GS, Tobin JD, Shocken D, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes. 1983;32(2):106–11. https://doi.org/10.2337/diab.32.2.106.
Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48(2):219–24. https://doi.org/10.1161/01.HYP.0000231552.10054.aa.
Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016;4(2):136–47. https://doi.org/10.1016/S2213-8587(15)00377-0.
Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65(5):1041–6. https://doi.org/10.1161/HYPERTENSIONAHA.114.05021.
Weir MR, Flack JM, Applegate WB. Tolerability, safety, and quality of life and hypertensive therapy: the case for low-dose diuretics. Am J Med. 1996;101(3A):83S–92S. https://doi.org/10.1016/S0002-9343(96)00271-9.
Price AL, Lingvay I, Szczepaniak EW, Wiebel J, Victor RG, Szczepaniak LS. The metabolic cost of lowering blood pressure with hydrochlorothiazide. Diabetol Metab Syndr. 2013;5(1):35. https://doi.org/10.1186/1758-5996-5-35.
Eriksson JW, Jansson PA, Carlberg B, Hagg A, Kurland L, Svensson MK, et al. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension. 2008;52(6):1030–7. https://doi.org/10.1161/HYPERTENSIONAHA.108.119404.
Muiesan ML, Salvetti M, Belotti E, Paini A, Rosei CA, Aggiusti C, et al. Effects of barnidipine in comparison with hydrochlorothiazide on endothelial function, as assessed by flow mediated vasodilatation in hypertensive patients. Blood Press. 2011;20(4):244–51. https://doi.org/10.3109/08037051.2011.561072.
Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.
Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med. 1998;158(7):741–51.
Dell'Omo G, Penno G, Del Prato S, Pedrinelli R. Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. J Cardiovasc Pharmacol Ther. 2005;10(4):265–72. https://doi.org/10.1177/107424840501000406.
Leonetti G, Rappelli A, Salvetti A, Scapellato L. Long-term effects of indapamide: final results of a two-year Italian multicenter study in systemic hypertension. Am J Cardiol. 1990;65(17):67H–H71. https://doi.org/10.1016/0002-9149(90)90347-4.
Harrower AD, McFarlane G. Antihypertensive therapy in diabetic patients. The use of indapamide. Am J Med. 1988;84(1B):89–91.
Osei K, Holland G, Falko JM. Indapamide. Effects on apoprotein, lipoprotein, and glucoregulation in ambulatory diabetic patients. Arch Intern Med. 1986;146(10):1973–7. https://doi.org/10.1001/archinte.1986.00360220131023.
Kuo SW, Pei D, Hung YJ, Hsieh AT, Wu LY, Hsieh CH, et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am J Hypertens. 2003;16(8):623–8.
Krum H, Skiba M, Gilbert RE. Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy. Diabet Med. 2003;20(9):708–12. https://doi.org/10.1046/j.1464-5491.2003.01023.x.
Vinereanu D, Dulgheru R, Magda S, Dragoi Galrinho R, Florescu M, Cinteza M, et al. The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial. Am Heart J. 2014;168(4):446–56. https://doi.org/10.1016/j.ahj.2014.06.010.
Emdin CA, Anderson SG, Woodward M, Rahimi K. Usual blood pressure and risk of new-onset diabetes: evidence from 4.1 million adults and a meta-analysis of prospective studies. J Am Coll Cardiol. 2015;66(14):1552–62. https://doi.org/10.1016/j.jacc.2015.07.059.
Ong KL, Barter PJ, Waters DD. Cardiovascular drugs that increase the risk of new-onset diabetes. Am Heart J. 2014;167(4):421–8. https://doi.org/10.1016/j.ahj.2013.12.025.
Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24(1):3–10. https://doi.org/10.1097/01.hjh.0000194119.42722.21.
Alderman MH. New onset diabetes during antihypertensive therapy. Am J Hypertens. 2008;21(5):493–9. https://doi.org/10.1038/ajh.2008.17.
Ueda S, Morimoto T, Ando S, Takishita S, Kawano Y, Shimamoto K, et al. A randomised controlled trial for the evaluation of risk for type 2 diabetes in hypertensive patients receiving thiazide diuretics: Diuretics In the Management of Essential hypertension (DIME) study. BMJ Open. 2014;4(7):e004576. https://doi.org/10.1136/bmjopen-2013-004576.
Lip S, Jeemon P, McCallum L, Dominiczak AF, McInnes GT, Padmanabhan S. Contrasting mortality risks among subgroups of treated hypertensive patients developing new-onset diabetes. Eur Heart J. 2016;37(12):968–74. https://doi.org/10.1093/eurheartj/ehv557.
Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201–7. https://doi.org/10.1016/S0140-6736(07)60108-1.
Nizamuddin M, Elliott WJ. Incident diabetes with antihypertensive drugs: updated network and Bayesian meta-analyses of clinical trial data. J Am Soc Hypertension. 2015;9(Suppl):e24. https://doi.org/10.1016/j.jash.2015.03.057.
Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med. 1993;118(4):273–8. https://doi.org/10.7326/0003-4819-118-4-199302150-00005.
Barzilay JI, Cutler JA, Davis BR. Antihypertensive medications and risk of diabetes mellitus. Curr Opin Nephrol Hypertens. 2007;16(3):256–60. https://doi.org/10.1097/MNH.0b013e328057dea2.
Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, et al. The metabolic syndrome in hypertension: European Society of Hypertension Position Statement. J Hypertens. 2008;26(10):1891–900. https://doi.org/10.1097/HJH.0b013e328302ca38.
Owen JG, Reisin E. Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications. Curr Hypertens Rep. 2015;17(6):558. https://doi.org/10.1007/s11906-015-0558-9.
Arroll B, Kenealy T, Elley CR. Should we prescribe diuretics for patients with prediabetes and hypertension? BMJ. 2008;337(aug21 1):a679. https://doi.org/10.1136/bmj.a679.
Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43(1):4–9. https://doi.org/10.1161/01.HYP.0000103632.19915.0E.
Musini VM, Nazer M, Bassett K, Wright JM. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;5:CD003824. https://doi.org/10.1002/14651858.CD003824.pub2.
Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534–44. https://doi.org/10.1001/jama.289.19.2534.
Psaty BM, Lumley T, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA. 2004;292(1):43–4. https://doi.org/10.1001/jama.292.1.43-c.
• Chen P, Chaugai S, Zhao F, Wang DW. Cardioprotective effect of thiazide-like diuretics: a meta-analysis. Am J Hypertens. 2015;28(12):1453–63. https://doi.org/10.1093/ajh/hpv050. This meta-analysis concludes that thiazide-like diuretics have greater protective effect against cardiovascular events than thiazide-type diuretics, especially on heart failure.
• Olde Engberink RH, Frenkel WJ, van den Bogaard B, Brewster LM, Vogt L, van den Born BJ. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension. 2015;65(5):1033–40. https://doi.org/10.1161/HYPERTENSIONAHA.114.05122. This systematic review concludes that the best available evidence seems to favor thiazide-like diuretics as the drug of choice when thiazide treatment is considered for hypertension.
Vongpatanasin W. Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic. Curr Opin Cardiol. 2015;30(4):361–5. https://doi.org/10.1097/HCO.0000000000000178.
•• de Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(9):1273–84. https://doi.org/10.2337/dci17-0026. This Position Statement is intended to update the assessment and treatment of hypertension among patients with diabetes, including advances in care.
Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016;352:i438. https://doi.org/10.1136/bmj.i438.
American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care. 2017;40(Suppl 1):S1–S135.
Lievre M, Gueyffier F, Ekbom T, Fagard R, Cutler J, Schron E, et al. Efficacy of diuretics and beta-blockers in diabetic hypertensive patients. Results from a meta-analysis. The INDANA Steering Committee. Diabetes Care. 2000;23(Suppl 2):B65–71.
Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996;276(23):1886–92. https://doi.org/10.1001/jama.1996.03540230036032.
Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95(1):29–35. https://doi.org/10.1016/j.amjcard.2004.08.059.
Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–40. https://doi.org/10.1016/S0140-6736(07)61303-8.
Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A, Group CS. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care. 2001;24(12):2091–6.
Lindholm LH, Hansson L, Ekbom T, Dahlof B, Lanke J, Linjer E, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens. 2000;18(11):1671–5. https://doi.org/10.1097/00004872-200018110-00020.
Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, et al. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension. 2003;41(3):431–6. https://doi.org/10.1161/01.HYP.0000057420.27692.AD.
Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010;56(1):77–85. https://doi.org/10.1016/j.jacc.2010.02.046.
Puig JG, Marre M, Kokot F, Fernandez M, Jermendy G, Opie L, et al. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am J Hypertens. 2007;20(1):90–7. https://doi.org/10.1016/j.amjhyper.2006.05.018.
Zhang Y, Agnoletti D, Wang JG, Xu Y, Safar ME. Natriuresis and blood pressure reduction in hypertensive patients with diabetes mellitus: the NESTOR study. J Am Soc Hypertens. 2015;9(1):21–8. https://doi.org/10.1016/j.jash.2014.10.003.
Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98. https://doi.org/10.1056/NEJMoa0801369.
Farsang C. Efficacy and tolerability of fixed-dose combination of perindopril/indapamide in type 2 diabetes mellitus: PICASSO trial. Adv Ther. 2014;31(3):333–44. https://doi.org/10.1007/s12325-014-0107-y.
Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56(19):1527–34. https://doi.org/10.1016/j.jacc.2010.06.034.
Patterson JH, Adams KF Jr. Investigating the role of thiazide-like diuretics in acute heart failure: potential approach to an unmet need. J Card Fail. 2016;22(7):537–8. https://doi.org/10.1016/j.cardfail.2016.05.001.
Trullas JC, Morales-Rull JL, Casado J, Freitas Ramirez A, Manzano L, Formiga F, et al. Rationale and design of the “Safety and Efficacy of the Combination of Loop with Thiazide-type Diuretics in Patients with Decompensated Heart Failure (CLOROTIC) Trial”: a double-blind, randomized, placebo-controlled study to determine the effect of combined diuretic therapy (loop diuretics with thiazide-type diuretics) among patients with decompensated heart failure. J Card Fail. 2016;22(7):529–36. https://doi.org/10.1016/j.cardfail.2015.11.003.
Sica DA. Diuretic use in renal disease. Nat Rev Nephrol. 2011;8(2):100–9. https://doi.org/10.1038/nrneph.2011.175.
Izzo JL Jr, Tobe SW. Is there a preferred diuretic class for patients with renal impairment and hypertension? J Am Soc Hypertens. 2016;10(4):282–4. https://doi.org/10.1016/j.jash.2016.02.008.
Elliott WJ, Jurca S. Loop diuretics are most appropriate for hypertension treatment in chronic kidney disease. J Am Soc Hypertens. 2016;10(4):285–7. https://doi.org/10.1016/j.jash.2016.02.007.
Karadsheh F, Weir MR. Thiazide and thiazide-like diuretics: an opportunity to reduce blood pressure in patients with advanced kidney disease. Curr Hypertens Rep. 2012;14(5):416–20. https://doi.org/10.1007/s11906-012-0293-4.
Kwakernaak AJ, Krikken JA, Binnenmars SH, Visser FW, Hemmelder MH, Woittiez AJ, et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. Lancet Diabetes Endocrinol. 2014;2(5):385–95. https://doi.org/10.1016/S2213-8587(14)70030-0.
Hoshino T, Ookawara S, Miyazawa H, Ito K, Ueda Y, Kaku Y, et al. Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease. Clin Exp Nephrol. 2015;19(2):247–53. https://doi.org/10.1007/s10157-014-0981-2.
Donnelly R, Molyneaux LM, Willey KA, Yue DK. Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Am J Cardiol. 1996;77(6):26B–30B. https://doi.org/10.1016/S0002-9149(97)89237-5.
Marre M, Puig JG, Kokot F, Fernandez M, Jermendy G, Opie L, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens. 2004;22(8):1613–22. https://doi.org/10.1097/01.hjh.0000133733.32125.09.
Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes preterax in albuminuria regression: PREMIER. Hypertension. 2003;41(5):1063–71. https://doi.org/10.1161/01.hyp.0000064943.51878.58.
Heerspink HJ, Ninomiya T, Perkovic V, Woodward M, Zoungas S, Cass A, et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J. 2010;31(23):2888–96. https://doi.org/10.1093/eurheartj/ehq139.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33–59. https://doi.org/10.1007/s40265-014-0337-y.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720.
McMurray J. EMPA-REG—the “diuretic hypothesis”. J Diabetes Complicat. 2016;30(1):3–4. https://doi.org/10.1016/j.jdiacomp.2015.10.012.
Scheen AJ. Reappraisal of the diuretic effect of empagliflozin in EMPA-REG OUTCOME: comparison with classic diuretics. Diabetes Metab. 2016;42(4):224–33. https://doi.org/10.1016/j.diabet.2016.05.006.
Scheen AJ, Delanaye P. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Metab. 2017;43(2):99–109. https://doi.org/10.1016/j.diabet.2016.12.010.
Devineni D, Vaccaro N, Polidori D, Rusch S, Wajs E. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Clin Ther. 2014;36(5):698–710. https://doi.org/10.1016/j.clinthera.2014.02.022.
Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obesity Metab. 2013;15(9):853–62. https://doi.org/10.1111/dom.12127.
Amin NB, Wang X, Mitchell JR, Lee DS, Nucci G, Rusnak JM. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obesity Metab. 2015;17(8):805–8. https://doi.org/10.1111/dom.12486.
Heise T, Mattheus M, Woerle HJ, Broedl UC, Macha S. Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study. Clin Ther. 2015;37(4):793–803. https://doi.org/10.1016/j.clinthera.2014.12.018.
Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, et al. Acute pharmacodynamic effects of empagliflozin with and without diuretic agents in patients with type 2 diabetes mellitus. Clin Ther. 2016;38(10):2248–64 e5. https://doi.org/10.1016/j.clinthera.2016.08.008.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. https://doi.org/10.1056/NEJMoa1611925.